Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of PF-06823859 in Adult Dermatomyositis
2020-004228-41Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dermatomyositis (DM) comparing PF-06823859 with Placebo (2 arms). Primary endpoint: Primary endpoints for Stage 1, Stage 2, and amended Stage 2. Started Feb 2021; status: completed.
02
Drugs
dazukibart
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on 2020-004228-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004228-41.